L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor
about
Opportunities and challenges for direct C-H functionalization of piperazinesThe aminoindanol core as a key scaffold in bifunctional organocatalystsViability of a drug-resistant human immunodeficiency virus type 1 protease variant: structural insights for better antiviral therapyHIV-1 Protease Inhibitors from Inverse Design in the Substrate Envelope Exhibit Subnanomolar Binding to Drug-Resistant VariantsABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humansBMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agentsIn vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632Inhibition of human immunodeficiency virus type 1 transcription and replication by DNA sequence-selective plant lignansSDZ PRI 053, an orally bioavailable human immunodeficiency virus type 1 proteinase inhibitor containing the 2-aminobenzylstatine moietyIn vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl proteaseProtein structure-based design of potent orally bioavailable, nonpeptide inhibitors of human immunodeficiency virus proteaseAntiviral properties of aminodiol inhibitors against human immunodeficiency virus and proteaseSelection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitorCharacterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitorHuman immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitorsAntiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 proteaseEvaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replicationAntiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus proteaseAnalysis of the S3 and S3' subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivoGenetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitorChemical ecology: a view from the pharmaceutical industryNelfinavir mesylate: a protease inhibitor.Conserved cysteines of the human immunodeficiency virus type 1 protease are involved in regulation of polyprotein processing and viral maturation of immature virionsPharmacokinetics of the protease inhibitor KNI-272 in plasma and cerebrospinal fluid in nonhuman primates after intravenous dosing and in human immunodeficiency virus-infected children after intravenous and oral dosingHigh-level resistance to 3'-azido-3'-deoxythimidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1The human immunodeficiency virus type 1 gag gene encodes an internal ribosome entry site.Mutations that abrogate human immunodeficiency virus type 1 reverse transcriptase dimerization affect maturation of the reverse transcriptase heterodimer.HIV-1 protease inhibitors.Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapyComparison of human immunodeficiency virus type 1 Pr55(Gag) and Pr160(Gag-pol) processing intermediates that accumulate in primary and transformed cells treated with peptidic and nonpeptidic protease inhibitorsInterference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1.Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource SettingsFormal Estimation of Errors in Computed Absolute Interaction Energies of Protein-ligand ComplexesEffects of ritonavir on indinavir pharmacokinetics in cerebrospinal fluid and plasma.Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjectsRemoval of human immunodeficiency virus type 1 (HIV-1) protease inhibitors from preparations of immature HIV-1 virions does not result in an increase in infectivity or the appearance of mature morphologyBoth P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitorPairwise additivity of energy components in protein-ligand binding: the HIV II protease-Indinavir case.Pharmacokinetic optimization of 4-substituted methoxybenzoyl-aryl-thiazole and 2-aryl-4-benzoyl-imidazole for improving oral bioavailability.
P2860
Q26747277-D148505A-BD7E-4540-9460-164F72E7282FQ26747294-29BBCA40-E679-470C-96AB-91160A80C27AQ27640250-D7E41BAD-E0D5-4C58-BFA2-CD3976E43F0BQ27650325-8A16165B-D324-41CB-8CD7-91BD0BECD007Q27729982-E45CDD51-479B-4AF4-A112-7EA2B852B99DQ28344472-ABFAA657-C22A-4E6F-8387-9863AD104D0FQ28344594-F33564BE-E50C-42D8-979D-5AD684427849Q28367369-FCF50C70-0B00-4E17-BAEC-D612534734D4Q28367430-F4A446D3-8705-4612-92E9-4711B290E818Q28367941-95645BC2-38F8-4C96-AC9A-5316B52F742DQ28368080-0DD76DF1-8B76-4B5A-ADCB-77EC9DAB4E09Q28368090-278837DA-8F84-40E8-9D33-A26276A924D9Q28368263-912E330F-A47C-45B4-A963-A0959D5B4446Q28368832-921572FB-C6C8-43AF-B325-768E55A9D7FEQ28378853-C970E4DA-5A30-46AD-939C-65C0E3E9CD4CQ28378879-E3748673-A547-4899-BB2D-AF4FEBB8A552Q28378991-029268C4-724C-46FB-963C-A77115DD21E1Q28379166-6151282A-6C03-4AA5-BF53-05F77BB6C2B2Q28379312-5A3B0173-F24A-44D1-A185-3B0EC6BC9E90Q28379356-C9FC6D0B-59D7-49E3-8083-C573056E86C3Q30418854-AD920256-B4F3-49BF-80AD-D69829057DB7Q33592439-3482753E-90EA-47FB-8314-B77844C91CB7Q33640739-A2DDB264-2CC2-4799-B549-D67ED05657E2Q33694444-F43F320E-A8C0-4D20-A0DC-647B92C9681DQ33796791-C4B6A13A-9EA0-47D0-BB7C-C69C93EEAFFCQ33834664-94FC26A6-6C25-4512-AA5A-1BBCDEB138B9Q33911895-9DFA759B-AF49-4DC7-A931-2B7341CC04C7Q33946920-7A1D2C10-CB13-4329-A438-A9967D2C1CA6Q33966329-92F027F9-A30E-4D0B-9EC2-40AFC0B0565BQ33979580-0F0437EC-B262-4C0E-91DA-0EE522656FB4Q34113737-DE1FA05C-559F-4162-8483-414295A0C9F8Q34730950-253D003B-DA80-49D8-B147-199C36547CC5Q35031108-4AEE991B-1FF3-48AA-B02B-D9FD0465CBC1Q35103600-584C8343-FF38-4DE6-9B4A-4793E43CB71CQ35134071-7E40F1C4-C8DF-423D-AE83-52E08DEFA0B4Q35135626-E773ABB1-02DE-434E-B675-10B954C15922Q35135963-9384F1F0-1667-4A76-93E6-E063F6D6D704Q35196297-0D7A07E2-5047-4668-A4EE-A2C806EC2031Q35237569-9DC6837A-7829-4C75-B2C2-72E944B2B9E8Q35264818-FF82F968-2772-41DE-9BB9-F4B21B8E46B1
P2860
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor
description
1994 nî lūn-bûn
@nan
1994 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor
@ast
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor
@en
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor
@nl
type
label
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor
@ast
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor
@en
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor
@nl
prefLabel
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor
@ast
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor
@en
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor
@nl
P2093
P2860
P356
P1476
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor
@en
P2093
B D Dorsey
J C Quintero
S L McDaniel
W A Schleif
P2860
P304
P356
10.1073/PNAS.91.9.4096
P407
P577
1994-04-26T00:00:00Z